Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
RX.Vthis companyBioSyent Inc.	CA$18.07	15.91×	3.46×	3.33×	10.19×	15.5%	74.6%	26.3%	20.9%	21.7%	20.0%	6.7%	0.02×	-1.6×	229.23×	5.51×	1.6%	5	10.66	4	A
CPH.TOCipher Pharmaceuticals Inc.	CA$13.71	10.06×	2.22×	5.44×	11.52×	423.7%	65.8%	32.7%	54.2%	22.1%	12.8%	10.8%	0.04×	-0.08×	14.17×	1.12×	0.0%	6	9.06	5	S-
CSCSCI.TOCOSCIENS Biopharma Inc.	CA$8.60	-0.21×	0.57×	0.29×	0.32×	-4514.4%	35.3%	-139.3%	-138.1%	-274.8%	-59.0%	-428.0%	0.56×	0.55×	-62.15×	3.18×	0.0%	5	0.24	2	C+
EBM.VEastwood Bio-Medical Canada Inc.	CA$1.88	-145.83×	-29.59×	61.66×	-155.88×	-105.3%	64.7%	-45.4%	-42.5%	20.4%	22.9%	0.0%	-0.05×	-0.19×	-39.38×	0.02×	0.0%	3	-6.4	1	C-
GUD.TOKnight Therapeutics Inc.	CA$11.75	-112.04×	0.79×	1.34×	11.11×	-352.6%	33.5%	-0.5%	-1.2%	-0.7%	-0.2%	11.4%	0.1×	0.03×	-0.21×	2.39×	0.0%	7	3.8	3	B-
MDP.TOMedexus Pharmaceuticals Inc.	CA$5.21	-44.57×	2.06×	1.02×	9.21×	-84.1%	54.8%	5.9%	-2.4%	-4.9%	6.1%	3.7%	0.45×	1.24×	1.12×	1.19×	0.0%	5	1.26	2	C
Peer median	—	-44.57×	0.79×	1.34×	9.21×	-105.3%	54.8%	-0.5%	-2.4%	-0.7%	6.1%	3.7%	0.1×	0.03×	-0.21×	1.19×	0.0%	5	1.26	2	—